HMG-CoA reductase inhibitor mevastatin enhances the growth ihibitory effect of butyrate in the colorectal carcinoma cell line Caco-2

Carcinogenesis

Volumn 22, Issue 7, 2001, Pages 1061-1067

  Wachtershauser A ^a   Akoglu, B ^a   Stein, J ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; BUTYRIC ACID; CHOLESTEROL; COMPACTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; FARNESYL TRANS TRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PROTEIN P21; PROTEIN P27; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; MITOSIS INHIBITION; PRIORITY JOURNAL; TIME;

EID: 0034930259     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/22.7.1061     Document Type: Article

References (57)

1. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac
2. Lovastatin induces apoptosis in malignant mesothelioma cells
3. The dual role of mevalonate in the cell cycle
4. Cholesterol inhibition, cancer and chemotherapy
5. Regulation of the mevalonate pathway
6. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
7. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
8. Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells
9. Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target
10. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
11. Safety and tolerability of cholesterol lowering agents with simvastatin during 5 years in Scandinavian simvastatin survival study
12. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats
13. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice
14. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man
15. Effect of short-chain fatty acids on the human colonic mucosa in vitro
16. Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice
17. Regulation of human colonic cell line proliferation and phenotype by sodium butyrate
18. Butyrate inhibits colon carcinoma cell growth through two distinct pathways
19. Mediation of differentiating effects of butyrate on the intestinal cell line Caco-2 by transforming growth factor-β1
20. PPAR-γ is selectively upregulated in Caco-2 cells by butyrate
21. Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis
22. Lovastatin sensitizes colon cancer HT-29 cells to apoptosis induced by chemotherapeutic agents
23. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion
24. Redistribution of the CDK inhibitor p27 between different cyclin. CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation
25. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
26. Expression of 5-lipoxygenase by human colorectal carcinoma Caco-2 cells during butyrate-induced cell differentiation
27. Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase 2 expression in HT-29 colonic epithelial cells
28. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells
29. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line
30. 1 arrest and suppression of CDK2 and CDK4
31. Butyrate-induced differentiation of Caco-2 cells is associated with apoptosis and early induction of p21Waf1/Cip1 and p27Kip1
32. Cdk inhibitors: On the threshold of checkpoints and development
33. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate
34. Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells
35. Analysis of IFN-γ-induced cell cycle arrest and cell death in hepatocytes
36. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
37. -/- human cancer cells
38. Kip1 accumulation during the cell cycle
39. 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase
40. Butyrate-induced differentiation of Caco-2 cells occurs independently from p27
41. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells
42. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: Implications for the possible role of dietary fibre in the prevention of large-bowel cancer
43. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells
44. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach
45. bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis
46. Expression of 15-lipoxygenase-1 in human colorectal cancer
47. Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation
48. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells
49. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
50. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia
51. Combined drug therapy-cholestyramine and compactin-for familial hypercholesterolemia
52. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine
53. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies
54. Cerivastatin in primary hyperlipidemia-a multicenter analysis of efficacy and safety
55. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
56. Rationale for the luminal provision of butyrate in intestinal diseases